Galapagos Nv Stock Earnings Reports

Galapagos (to be renamed Lakefront Biotherapeutics, ticker LKFT) reported Q1 2026 results and outlined a strategic transformation under CEO Henry Gosebruch after his first year. The company completed management and Board changes, rebranded, and entered a binding transaction with Gilead to acquire Ouro Medicines' portfolio led by gamgertamig, a BCMA/CD3 T-cell engager targeting autoimmune diseases with potential first-/best-in-class properties and registrational studies possible as early as 2027. Clinical experience from >60 patients across multiple autoimmune indications shows rapid, deep and durable B-cell depletion with minimal cytokine release at current schedules; Fast Track and Orphan designations exist for some indications. The deal also provides a partial waiver/modification of the legacy OLCA with Gilead, unlocking up to EUR 500 million of previously restricted capital (of which up to EUR 150 million may be used for return of capital subject to limits), and gives Galapagos greater strategic and financial flexibility including the ability to pursue BD independent of Gilead. Q1 revenues were EUR 6.5 million (down YoY due to prior-year OLCA-related recognition); operating loss improved to EUR 63.7 million and the company reported a net profit of EUR 14.5 million driven by favorable FX and fair value adjustments. Cash and investments were EUR 2.98 billion at March 31, 2026. Guidance includes Ouro-related cash spend (upfront ~EUR 713 million plus additional 2026 spend totaling EUR 775–790 million), one-time wind-down costs for cell therapy of EUR 125–175 million, and an expected year-end cash balance of EUR 1.975–2.05 billion. Management emphasized disciplined capital allocation, high standards for future BD, optionality for share repurchase subject to closing, and that the company remains well-funded to progress gamgertamig toward approval while retaining capital for additional strategic opportunities.